Dana Walker, vice president, Opdivo global programme lead, BMS, said: “HCC is the predominant type of liver cancer globally, including in the EU, and when diagnosed at the advanced or unresectable ...

The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...

For example, they may prescribe: angiogenesis inhibitors, such as bevacizumab (Avastin) kinase inhibitors, such as lenvatinib (Lenvima) mTOR inhibitors, such as everolimus (Affinitor) and ...

PRINCETON, N.J. - Bristol Myers Squibb (NYSE: BMY), a prominent pharmaceutical company with a market capitalization of nearly $120 billion and impressive gross profit margins of 76%, received a ...

Another option is MSD's immunotherapy Keytruda (pembrolizumab) and Eisai’s Lenvima (lenvatinib), which was also given the go-ahead in 2022. The new guidance says that the Cabometyx/Opdivo ...

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the ...

The 12-month open-label extension of the PACIFIC trial demonstrated that bexicaserin significantly reduced seizure frequency in patients with developmental and epileptic encephalopathies while ...

Autoimmune thyroid disease (AITD) causes cellular damage and alters thyroid gland function by humoral and cell-mediated mechanisms. Cellular damage occurs when sensitized T-lymphocytes and/or ...

The clinical use of TRAb measurements for the diagnosis and follow-up of AITD remains a matter of controversy and differs geographically. The differential diagnosis of hyperthyroidism can be ...

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.

Although numerous anti-angiogenic agents have been tested or are under development, sorafenib, regorafenib, and lenvatinib are currently the only anti-angiogenic agents approved globally to enhance ...